142 related articles for article (PubMed ID: 31427055)
1. Checkpoint inhibitor-associated autoimmunity.
Ladak K; Bass AR
Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):781-802. PubMed ID: 31427055
[TBL] [Abstract][Full Text] [Related]
2. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist.
Jamal S; Hudson M; Fifi-Mah A; Ye C
J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203
[TBL] [Abstract][Full Text] [Related]
3. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Abdel-Wahab N; Suarez-Almazor ME
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence and treatment of rheumatological adverse events due to immune checkpoint inhibitor therapy].
Verspohl SH; Schulze-Koops H; Heine A; Schäfer VS
Z Rheumatol; 2020 Oct; 79(8):797-808. PubMed ID: 32926217
[TBL] [Abstract][Full Text] [Related]
5. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.
Roberts J; Ennis D; Hudson M; Ye C; Saltman A; Himmel M; Rottapel R; Pope J; Hoa S; Tisseverasinghe A; Fifi-Mah A; Maltez N; Jamal S
Autoimmun Rev; 2020 Aug; 19(8):102595. PubMed ID: 32535092
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory markers in autoimmunity induced by checkpoint inhibitors.
Husain B; Kirchberger MC; Erdmann M; Schüpferling S; Abolhassani AR; Fröhlich W; Berking C; Heinzerling L
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1623-1630. PubMed ID: 33837821
[TBL] [Abstract][Full Text] [Related]
7. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
[TBL] [Abstract][Full Text] [Related]
8. Neuromuscular complications of immune checkpoint inhibitors.
Psimaras D
Presse Med; 2018; 47(11-12 Pt 2):e253-e259. PubMed ID: 30413332
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy.
He X; Yu J; Shi H
Front Pharmacol; 2021; 12():797852. PubMed ID: 34899357
[TBL] [Abstract][Full Text] [Related]
11. [A review of immune-related adverse events associated with immunotherapy].
Fang Y; Yu Y; Wu DW; Fang H; Huang HY; Wang SH; Yu AQ; Sun C; Bai Y; Wang H; Li N
Zhonghua Zhong Liu Za Zhi; 2020 Jan; 42(1):17-21. PubMed ID: 32023764
[TBL] [Abstract][Full Text] [Related]
12. [Rheumatological complications of immune checkpoint inhibitor therapy].
Lazarou I; Fernandez E
Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.
Tocut M; Brenner R; Zandman-Goddard G
Autoimmun Rev; 2018 Jun; 17(6):610-616. PubMed ID: 29631064
[TBL] [Abstract][Full Text] [Related]
14. Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy.
Dey A; Manolios N; Long GV; Carlino MS; Kefford R; Schrieber L
Intern Med J; 2022 May; 52(5):818-827. PubMed ID: 33135853
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
16. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.
Couey MA; Bell RB; Patel AA; Romba MC; Crittenden MR; Curti BD; Urba WJ; Leidner RS
J Immunother Cancer; 2019 Jul; 7(1):165. PubMed ID: 31269983
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma.
Wölffer M; Battke F; Schulze M; Feldhahn M; Flatz L; Martus P; Forschner A
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053465
[TBL] [Abstract][Full Text] [Related]
18. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
19. Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey.
da Silva GFM; Landim JIVD; Dos Santos Brasil LT; Plens ICM; Silva ALC; Scheinberg MA; Rocha FAC
Rheumatol Int; 2021 May; 41(5):939-942. PubMed ID: 32767082
[TBL] [Abstract][Full Text] [Related]
20. Enterocolitis due to immune checkpoint inhibitors: a systematic review.
Soularue E; Lepage P; Colombel JF; Coutzac C; Faleck D; Marthey L; Collins M; Chaput N; Robert C; Carbonnel F
Gut; 2018 Nov; 67(11):2056-2067. PubMed ID: 30131322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
